Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling - PubMed (original) (raw)

Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling

Thierry Léveillard et al. Sci Transl Med. 2010.

Abstract

The identification of one mechanism that causes vision loss in inherited degenerative retinal disorders revealed a new signaling molecule that represents a potential therapy for these currently untreatable diseases. This protein, called rod-derived cone viability factor (RdCVF), maintains the function and consequently the viability of cone photoreceptor cells in the retina; mice that lack this factor exhibit a progressive loss of photoreceptor cells. The gene encoding RdCVF also encodes, by differential splicing, a second product that has characteristics of a thioredoxin-like enzyme and protects both photoreceptor cells and, more specifically, its interacting protein partner, the tau protein, against oxidative damage. This signaling pathway potentially links environmental insults to an endogenous neuroprotective response.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: T.L. and J-A.S. are patent-holders on the use of RdCVF and RdCVF2 for the treatment of retinal and neurological disease

Figures

Fig. 1

Fig. 1. Organization of the retina

CREDIT: C. BICKEL/SCIENCE TRANSLATIONAL MEDICINE

Fig. 2

Fig. 2. Schematic representation of the Nxnl1 gene and its two products, RdCVF and RdCVFL

Alternative splicing generates the truncated trophic factor and the longer thioredoxin-like enzyme. In the ribbon diagrams, the thioredoxin catalytic site is shown in yellow, the shared portion of the thioredoxin fold in red, the additional thioredoxin fold (found only in RdCVFL) in green, and the RdCVF specific loops in blue. CREDIT: C. BICKEL/SCIENCE TRANSLATIONAL MEDICINE

Fig. 3

Fig. 3. Maintenance of the cone outer segment by RdCVF

RdCVF was injected into eyes of the P23H rat, a model of autosomal dominant RP. The cone cells (green) of the RdCVF-injected animal (bottom panel) display a longer outer segment (indicated by double arrows) and smaller diameter (asterisk) than those in the vehicle-injected rat (top panel). The relative positions of the cone outer segment in each case are indicated on the diagram on the right.

Similar articles

Cited by

References

    1. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying GS, Ziviello C, Acerra C, Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A. Gene Therapy for Leber’s Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration. Mol Ther. 2009 Dec 1; [Epub ahead of print] - PMC - PubMed
    1. Hamel CP, Tsilou E, Pfeffer BA, Hooks JJ, Detrick B, Redmond TM. Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro. J Biol Chem. 1993;268:15751–15757. - PubMed
    1. Marlhens F, Bareil C, Griffoin JM, Zrenner E, Amalric P, Eliaou C, Liu SY, Harris E, Redmond TM, Arnaud B, Claustres M, Hamel CP. Mutations in RPE65 cause Leber’s congenital amaurosis. Nat Genet. 1997;17:139–141. - PubMed
    1. Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U, Nicoletti A, Murthy KR, Rathmann M, Kumaramanickavel G, Denton MJ, Gal A. Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet. 1997;17:194–197. - PubMed
    1. Aguirre GD, Baldwin V, Pearce-Kelling S, Narfström K, Ray K, Acland GM. Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect. Mol Vis. 1998;4:23. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources